Markets:

Overview

News

Currencies

International

Treasuries

scPharmaceuticals Inc. - Common Stock (NQ:SCPH)

5.670 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 6, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about scPharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 Next >

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZIMV, ARIS, SCPH on Behalf of Shareholders

September 16, 2025

From Halper Sadeh LLC

Via GlobeNewswire

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

September 16, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Insights Ahead: scPharmaceuticals's Quarterly Earnings ↗

May 13, 2025

Via Benzinga

Earnings Scheduled For November 13, 2024 ↗

November 13, 2024

Via Benzinga

scPharmaceuticals's Earnings Outlook ↗

November 12, 2024

Via Benzinga

Unusual volume stocks in Friday's session ↗

August 29, 2025

Let's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMXI, HBI, VTLE, SCPH on Behalf of Shareholders

August 28, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)

August 28, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

August 26, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders

August 26, 2025

From Halper Sadeh LLC

Via GlobeNewswire

MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish ↗

August 25, 2025

The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.

Via Stocktwits

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal ↗

August 25, 2025

MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity.

Via Benzinga

SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders

August 25, 2025

From Halper Sadeh LLC

Via Business Wire

Which stocks are moving before the opening bell on Monday? ↗

August 25, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders

August 25, 2025

From Ademi & Fruchter LLP

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 25, 2025

Via Benzinga

MannKind Corporation to Acquire scPharmaceuticals: More Details Inside ↗

August 25, 2025

The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.

Via Stocktwits

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

August 25, 2025

From MannKind

Via GlobeNewswire

SCPH Revenue Up 99% ↗

August 07, 2025

Via The Motley Fool

Which stocks are moving before the opening bell on Tuesday? ↗

April 22, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Analyst Expectations For scPharmaceuticals's Future ↗

March 20, 2025

Via Benzinga

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 19, 2025

From scPharmaceuticals Inc.

Via GlobeNewswire

Earnings Scheduled For May 14, 2025 ↗

May 14, 2025

Via Benzinga

Earnings Scheduled For March 19, 2025 ↗

March 19, 2025

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

March 06, 2025

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

March 06, 2025

From scPharmaceuticals Inc.

Via GlobeNewswire

SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024 ↗

August 14, 2024

SCPH stock results show that scPharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization ↗

August 12, 2024

FDA approves scPharmaceuticals' expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuticals secures $125M non-dilutive financing to repay debt and advance...

Via Benzinga

7 Short-Squeeze Stocks That Could Beat Down the Bears ↗

July 15, 2024

Panic can be a cruel emotion, especially when the consequences are uncapped red ink.

Via InvestorPlace

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.